)| PMID |
18210200 ( ) |
|---|---|
| Title | Novel nanomaterials for clinical neuroscience. |
| Abstract | Neurodegenerative disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population ages. The field of nanomedicine is rapidly expanding and promises revolutionary advances to the diagnosis and treatment of devastating human diseases. This paper provides an overview of novel nanomaterials that have potential to improve diagnosis and therapy of neurodegenerative disorders. Examples include liposomes, nanoparticles, polymeric micelles, block ionomer complexes, nanogels, and dendrimers that have been tested clinically or in experimental models for delivery of drugs, genes, and imaging agents. More recently discovered nanotubes and nanofibers are evaluated as promising scaffolds for neuroregeneration. Novel experimental neuroprotective strategies also include nanomaterials, such as fullerenes, which have antioxidant properties to eliminate reactive oxygen species in the brain to mitigate oxidative stress. Novel technologies to enable these materials to cross the blood brain barrier will allow efficient systemic delivery of therapeutic and diagnostic agents to the brain. Furthermore, by combining such nanomaterials with cell-based delivery strategies, the outcomes of neurodegenerative disorders can be greatly improved. Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE 68198, USA. on NeuroImmune Pharmacology |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 6081 | INS | insulin | 3 | insulin | |
| 1516 | CAT | catalase | 3 | catalase | |
| 11740 | TF | transferrin | 3 | transferrin | |
| 1033 | BDNF | brain-derived neurotrophic factor | 2 | brain derived neurotrophic factor | |
| 727 | ARTN | artemin | 1 | neurotrophic factor | |
| 19986 | CYCS | cytochrome c, somatic | 1 | cytochrome c | |
| 4232 | GDNF | glial cell derived neurotrophic factor | 1 | glial derived neurotrophic factor | |
| 399 | ALB | albumin | 1 | albumin | |
| 1678 | CD4 | CD4 molecule | 1 | CD4 | |
| 4827 | HBB | hemoglobin, beta | 1 | hemoglobin | |
| 7808 | NGF | nerve growth factor (beta polypeptide) | 1 | nerve growth factor | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 4827 | HBB | hemoglobin, beta | hemoglobin | 1.0 | also been used to produce nanotubes with glucose oxidase and hemoglobin (Hou Hou et al 2005b |
| 1678 | CD4 | CD4 molecule | CD4 | 0.6 | plasma lymph nodes spleen liver and lung as well as CD4 T-cell protection |
| 727 | ARTN | artemin | neurotrophic factor | 1.0 | another study also suggested that cnts functionalized with growth factors such as nerve growth factor or brain derived neurotrophic factor can stimulate growth of neurons on the nanotube scaffold matsumoto et al 2007 . |
| 7808 | NGF | nerve growth factor (beta polypeptide) | nerve growth factor | 1.0 | another study also suggested that cnts functionalized with growth factors such as nerve growth factor or brain derived neurotrophic factor can stimulate growth of neurons on the nanotube scaffold matsumoto et al 2007 . |
| 1033 | BDNF | brain-derived neurotrophic factor | brain derived neurotrophic factor | 1.0 | another study also suggested that cnts functionalized with growth factors such as nerve growth factor or brain derived neurotrophic factor can stimulate growth of neurons on the nanotube scaffold matsumoto et al 2007 . |
| 19986 | CYCS | cytochrome c, somatic | cytochrome c | 1.0 | for example a recent study reported a nanotube produced by a layer based assembly of cytochrome c poly sodium styrene sulfonate and poly ethylenimine pei . |
| 6081 | INS | insulin | insulin | 1.0 | omes to the brain they can be additionally modified vectorized with monoclonal antibodies to glial fibrillary acidic proteins pardridge 1999 ; chekhonin et al 2005 transferrin receptors ox26 or human insulin receptors 83 14 mab; pardridge 1999 . |
| 11740 | TF | transferrin | transferrin | 1.0 | to target pegylated liposomes to the brain they can be additionally modified vectorized with monoclonal antibodies to glial fibrillary acidic proteins pardridge 1999 ; chekhonin et al 2005 transferrin receptors ox26 or human insulin receptors 83 14 mab; pardridge 1999 . |
| 6081 | INS | insulin | insulin | 1.0 | one study has shown that polymeric micelles of pluronic block copolymers after conjugation with an antibody against a 2 glycoprotein or insulin showed increased delivery of a drug haloperidol or a fluorescent probe to the brain in vivo kabanov et al 1989 . |
| 6081 | INS | insulin | insulin | 1.0 | the permeability of oligonucleotides with nanogels was enhanced when the nanogel surface was modified with polypeptides transferrin or insulin that bind receptors at the luminal side of the brain microvessel endothelial cells and transport to their abluminal side. |
| 11740 | TF | transferrin | transferrin | 1.0 | the permeability of oligonucleotides with nanogels was enhanced when the nanogel surface was modified with polypeptides transferrin or insulin that bind receptors at the luminal side of the brain microvessel endothelial cells and transport to their abluminal side. |
| 11740 | TF | transferrin | transferrin | 1.0 | gene transfer into brain capillary cells have been also shown using a transferrin conjugated peg modified pamam dendrimer huang et al 2007 . |
| 399 | ALB | albumin | albumin | 1.0 | notably several nanoscale drugs _amp_#8220;nanomedicines_amp_#8221; such as liposomal doxorubicin doxil gabizon et al 2006 or albumin bound paclitaxel abraxane gradishar 2006 have been used in clinic already for treatment of cancer and other diseases. |
| 1516 | CAT | catalase | catalase | 1.0 | based on this our laboratories developed cell mediated delivery of catalase nanozyme to the brain to mitigate production of ros and induce neuroprotection batrakova et al 2007 . |
| 1516 | CAT | catalase | catalase | 1.0 | to preclude bmm mediated enzyme degradation catalase was packaged into a block ionomer complex with a cationic block copolymer pei peg. |
| 1516 | CAT | catalase | catalase | 1.0 | the self assembled catalase/pei peg complexes were ca. 60 to 100 nm in size stable in ph and ionic strength and retained antioxidant activities. |
| 4232 | GDNF | glial cell derived neurotrophic factor | glial derived neurotrophic factor | 1.0 | these diseases would collectively benefit from immunomodulation neurotrophic factors such as glial derived neurotrophic factor or brain derived neurotrophic factor and in the case of hiv 1 disease anti retroviral therapy kabanov and gendelman 2007 . |
| 1033 | BDNF | brain-derived neurotrophic factor | brain derived neurotrophic factor | 1.0 | these diseases would collectively benefit from immunomodulation neurotrophic factors such as glial derived neurotrophic factor or brain derived neurotrophic factor and in the case of hiv 1 disease anti retroviral therapy kabanov and gendelman 2007 . |